Prometheus Biosciences Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress - Advanced and expanded development of PRA023 across three immune-mediated indications - - Topline results from ARTEMIS-UC and APOLLO-CD Phase 2 studies on track for fourth quarter 2022 - -...

Prometheus Biosciences Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Progress - Full clinical trial results from Phase 1a trial of PRA023 and announcement of a third Phase 2 indication for PRA023 expected in fourth quarter 2021 - - Enrollment on track for Phase 2 in...

Prometheus Biosciences Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Progress - Initiated Phase 2 study of PRA023 and its companion diagnostic in Ulcerative Colitis (UC) and Phase 2a study of PRA023 and its companion diagnostic in Crohn’s disease (CD) - - Phase 1a trial...